Literature DB >> 27974808

Heart failure: Phase II trial results of omecamtiv mecarbil.

Gregory B Lim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27974808     DOI： 10.1038/nrcardio.2016.205

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.

Authors:  John R Teerlink; G Michael Felker; John J V McMurray; Scott D Solomon; Kirkwood F Adams; John G F Cleland; Justin A Ezekowitz; Assen Goudev; Peter Macdonald; Marco Metra; Veselin Mitrovic; Piotr Ponikowski; Pranas Serpytis; Jindrich Spinar; János Tomcsányi; Hans J Vandekerckhove; Adriaan A Voors; Maria Laura Monsalvo; James Johnston; Fady I Malik; Narimon Honarpour
Journal:  Lancet       Date:  2016-12-01       Impact factor: 79.321
  1 in total
  2 in total

Review 1.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.

Authors:  Giuliana G Repetti; Christopher N Toepfer; Jonathan G Seidman; Christine E Seidman
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

2.  Single molecule turnover of fluorescent ATP by myosin and actomyosin unveil elusive enzymatic mechanisms.

Authors:  Marko Ušaj; Luisa Moretto; Venukumar Vemula; Aseem Salhotra; Alf Månsson
Journal:  Commun Biol       Date:  2021-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.